Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
The major clinical obstacle that limits the long-term benefits of treatment with osimertinib...
Read More